Insmed Inc (INSM)vsQ32 Bio Inc (QTTB)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
QTTB
Q32 Bio Inc
$7.25
-0.68%
HEALTHCARE · Cap: $98.89M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1029% more annual revenue ($606.42M vs $53.74M). QTTB leads profitability with a 55.5% profit margin vs -2.1%. QTTB earns a higher WallStSmart Score of 60/100 (C).
INSM
Hold39
out of 100
Grade: F
QTTB
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+76.7%
Fair Value
$16.46
Current Price
$7.25
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Every $100 of equity generates 125 in profit
Keeps 56 of every $100 in revenue as profit
Strong operational efficiency at 85.4%
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : QTTB
The strongest argument for QTTB centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 55.5% and operating margin at 85.4%.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : QTTB
The primary concerns for QTTB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while QTTB is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
QTTB generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
QTTB scores higher overall (60/100 vs 39/100), backed by strong 55.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Q32 Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Q32 Bio Inc. is a pioneering biotechnology firm focused on developing innovative antibody-based therapies to address autoimmune diseases and enhance immune responses. Utilizing its proprietary technology platform, the company is advancing a robust pipeline of treatments designed to restore immune system balance. Backed by a seasoned management team and strategic collaborations, Q32 Bio is well-positioned to leverage its scientific expertise to meet significant unmet medical needs, thereby driving transformative advancements in healthcare and creating value for shareholders through sustained research and development initiatives.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?